期刊文献+

紫杉醇联合调强放疗对中晚期宫颈癌的疗效及血清OPN、MMP-9表达水平的影响 被引量:4

Efficacy of Paclitaxel Combined with Intensity Modulated Radiation Therapy on Advanced Cervical Cancer and Expression of Serum OPN and MMP-9
在线阅读 下载PDF
导出
摘要 【目的】探讨紫杉醇联合调强放疗对中晚期宫颈癌的疗效及血清骨桥蛋白(OPN)、基质金属蛋白酶-9(MMP-9)表达水平的影响。【方法】两院收治的118例中晚期宫颈癌患者,按照治疗方案不同分为对照组与观察组。对照组:58例,均采用调强放疗+顺铂治疗;观察组:60例,在对照组治疗基础上予以紫杉醇治疗。比较两组患者近期疗效、远期疗效、不良反应发生情况及血清OPN、MMP-9的表达水平。【结果】观察组近期有效率为91.67%(55/60),对照组为84.48%(49/58),两组近期有效率比较,差异无统计学意义(P>0.05)。治疗后,两组血清OPN、MMP-9表达水平均低于治疗前(P<0.05),且观察组血清OPN、MMP-9表达水平均低于对照组(P<0.05)。两组近期不良反应发生率相比较,差异均无统计学意义(P>0.05)。观察组3年累积生存率为73.33%(44/60),显著高于对照组的51.72%(30/58),LogRank检验结果提示两组生存曲线整体比较,差异有统计学意义(P<0.05)。【结论】紫杉醇联合调强放疗治疗中晚期宫颈癌疗效明显,能下调患者血清OPN、MMP-9表达水平,提高远期生存率,且安全性可。 【Objective】To investigate the efficacy of paclitaxel combined with intensity modulated radiation therapy and its effects on the expression of osteopontin(OPN)and matrix metalloproteinase-9(MMP-9)in patients with advanced cervical cancer.【Methods】A total of 118 patients with advanced cervical cancer in our hospital,were divided into the control group and the observation group according to the treatment plan.The control group of 58 cases were treated with intensity modulated radiotherapy+cisplatin;the study group of 60 cases were treated with paclitaxel on the basis of the control group.The short-term efficacy,long-term efficacy and adverse reactions were compared between the two groups,and the expression levels of serum OPN and MMP-9 were detected and compared as well.【Results】The short-term effective rate of the observation group was 91.67%and that of the control group was 84.48%.However,there was no significant difference between the two groups(P>0.05).After treatment,the expression levels of serum OPN and MMP-9 in the two groups were lower than those before treatment(P<0.05);And the expression levels of serum OPN and MMP-9 in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of recent adverse reactions between the two groups(P>0.05).The 3-year cumulative survival rate of the observation group was 73.33%(44/60),which was significantly higher than that of the control group 51.72%(30/58),and the Log Rank test results indicated that the overall survival curves of the two groups were significantly different(P<0.05).【Conclusion】Paclitaxel combined with intensity modulated radiation therapy is effective in the treatment of advanced cervical cancer.It can down-regulate the expression of serum OPN and MMP-9,improve the long-term survival rate,and the safety is acceptable.
作者 张金涛 马显平 ZHANG Jin-tao;MA Xian-ping(Department of Oncology and Radiotherapy,Xi'an High-tech Hospital,Xi'an Shaanxi 710077)
出处 《医学临床研究》 CAS 2022年第6期881-884,共4页 Journal of Clinical Research
关键词 宫颈肿瘤/放射疗法 紫杉酚/治疗应用 金属蛋白酶类/血液 骨桥蛋白质/血液 Uterine Cervical Neoplasms/RT Paclitaxel/TU Metalloproteases/BL Osteopontin/BL
  • 相关文献

参考文献12

二级参考文献147

  • 1Jemal A,Siegel R,Ward E. Cancer Statistics,2007[J].{H}CA-A Cancer Journal for Clinicians,2007.43-66.
  • 2Howe HL,Wu X,Ries LA. Annual report to the nation on the status of cancer,1975-2003,featuring cancer among U.S.Hispanic/Latino populations[J].{H}CANCER,2006,(08):1711-1742.
  • 3Sherman ME,Wang SS,Carreon J. Mortality trends for cervical squamous and adenocarcinoma in the United States.Relation to incidence and survival[J].{H}CANCER,2005,(06):1258-1264.
  • 4Parkin DM,Bray F,Ferlay J. Global cancer statistics,2002[J].{H}CA-A Cancer Journal for Clinicians,2005.74-108.
  • 5Kamangar F,Dores GM,Anderson WF. Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world[J].{H}Journal of Clinical Oncology,2006,(14):2137-2150.
  • 6Villa LL,Costa RL,Petta CA. Prophylactic quadrivalent human papillomavirus(types 6,11,16,and 18)L1 virus-like particle vaccine in young women:a randomized double-blind placebo-controlled multicentre phase II efifcacy trial[J].{H}LANCET ONCOLOGY,2005.271-278.
  • 7Ault KA,Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2,grade 3,and adenocarcinoma in situ:a combined analysis of four randomised clinical trials[J].{H}LANCET,2007,(9576):1861-1868.
  • 8FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions[J].{H}New England Journal of Medicine,2007,(19):1915-1927.
  • 9Arbyn M,Dillner J. Review of current knowledge on HPV vaccination:an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening[J].{H}Journal of Clinical Virology,2007,(03):189-197.
  • 10American College of Obstetricians and Gynecologists. ACOG practice bulletin.Diagnosis and treatment of cervical carcinomas.Number 35,May 2002[J].{H}International Journal of Gynecology & Obstetrics,2002.79-91.

共引文献670

同被引文献52

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部